Intra-Cellular Therapies Price to Free Cash Flow Ratio 2013-2022 | ITCI
Historical price to free cash flow ratio values for Intra-Cellular Therapies (ITCI) since 2013.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
| Intra-Cellular Therapies Price to Free Cash Flow Ratio Historical Data |
| Date |
Stock Price |
TTM FCF per Share |
Price to FCF Ratio |
| 2022-08-05 |
59.99 |
|
0.00 |
| 2022-03-31 |
61.19 |
$-3.51 |
0.00 |
| 2021-12-31 |
52.34 |
$-3.20 |
0.00 |
| 2021-09-30 |
37.28 |
$-3.24 |
0.00 |
| 2021-06-30 |
40.82 |
$-3.11 |
0.00 |
| 2021-03-31 |
33.93 |
$-3.08 |
0.00 |
| 2020-12-31 |
31.80 |
$-3.27 |
0.00 |
| 2020-09-30 |
25.66 |
$-2.95 |
0.00 |
| 2020-06-30 |
25.67 |
$-2.65 |
0.00 |
| 2020-03-31 |
15.37 |
$-2.47 |
0.00 |
| 2019-12-31 |
34.31 |
$-2.33 |
0.00 |
| 2019-09-30 |
7.47 |
$-2.24 |
0.00 |
| 2019-06-30 |
12.98 |
$-2.22 |
0.00 |
| 2019-03-31 |
12.18 |
$-2.32 |
0.00 |
| 2018-12-31 |
11.39 |
$-2.17 |
0.00 |
| 2018-09-30 |
21.70 |
$-2.10 |
0.00 |
| 2018-06-30 |
17.67 |
$-1.92 |
0.00 |
| 2018-03-31 |
21.05 |
$-1.88 |
0.00 |
| 2017-12-31 |
14.48 |
$-1.76 |
0.00 |
| 2017-09-30 |
15.78 |
$-1.95 |
0.00 |
| 2017-06-30 |
12.42 |
$-2.30 |
0.00 |
| 2017-03-31 |
16.25 |
$-2.04 |
0.00 |
| 2016-12-31 |
15.09 |
$-2.11 |
0.00 |
| 2016-09-30 |
15.24 |
$-2.39 |
0.00 |
| 2016-06-30 |
38.82 |
$-3.10 |
0.00 |
| 2016-03-31 |
27.80 |
$-3.31 |
0.00 |
| 2015-12-31 |
53.79 |
$-3.09 |
0.00 |
| 2015-09-30 |
40.04 |
$-2.31 |
0.00 |
| 2015-03-31 |
23.88 |
$-1.06 |
0.00 |
| 2014-12-31 |
17.65 |
$-0.80 |
0.00 |
| 2014-09-30 |
13.71 |
$-1.92 |
0.00 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$5.659B |
$0.084B |
|
Intra-Cellular Therapies Inc. is a biopharmaceutical company. The company develops drugs for the treatment of neuropsychiatric and neurologic diseases and other disorders of the central nervous system. Its product candidates include ITI-007, ITI-002 and ITI-009 which is in clinical trials. Intra-Cellular Therapies Inc. is headquartered in New York.
|
